Trial and Protocol Number Solid Tumor |
| Phase II |
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors
NCI-09-C-0138
| Principal Investigator: | Referral Contact: | | Shivaani Kummar | Janelle Bingham | | 301-435-5402 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes
NCI-09-C-0047
| Principal Investigator: | Referral Contact: | | Steven A. Rosenberg | Linda Williams | 1-866-820-4505 (Toll Free) | 1-866-820-4505 (Toll Free) | | ncisbirc@mail.nih.gov
|
|
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121
| Principal Investigator: | Referral Contact: | | Steven A. Rosenberg | Linda Williams | 1-866-820-4505 (Toll Free) | 1-866-820-4505 (Toll Free) | | ncisbirc@mail.nih.gov
|
|
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases
NCI-07-C-0230
| Principal Investigator: | Referral Contact: | | Deborah Citrin | Sharon L. Smith | | 301-496-5457 | 301-496-5457 | | smiths@mail.nih.gov
|
|
| Phase I |
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCI-09-C-0173
| Principal Investigator: | Referral Contact: | | Richard Piekarz | Robin Frye | | 301-496-1196 | 301-402-5958 | | fryer@mail.nih.gov
|
|
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression
NCI-09-C-0168
| Principal Investigator: | Referral Contact: | | Elise C. Kohn | Laura D. Otten | | 301-402-2726 | 301-451-1228 1-866-611-6310 (Toll Free) | | ottenl@mail.nih.gov
|
|
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
NCI-09-C-0111
| Principal Investigator: | Referral Contact: | | Susan Bates | Debbie Draper | | 301-402-1357 | 301-435-8525 | | draperde@mail.nih.gov
|
|
An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing Carcinoma
NCI-09-C-0101
| Principal Investigator: | Referral Contact: | | James L. Gulley | Laura D. Otten | | 301-435-2956 | 301-451-1228 1-866-611-6310 (Toll Free) | | ottenl@mail.nih.gov
|
|
A Targeted Phase I Trial of ZD6474 (Vandetanib; ZACTIMA®) Plus the Proteasome Inhibitor Bortezomib (Velcade®) in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
NCI-09-C-0089
| Principal Investigator: | Referral Contact: | | Antonio Tito Fojo | Maureen Edgerly | | 301-402-1357 | 301-435-5604 | | edgerlym@mail.nih.gov
|
|
A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas
NCI-09-C-0048
| Principal Investigator: | Referral Contact: | | Shivaani Kummar | Deborah Allen | | 301-435-5402 | 301-402-5640 | | allendeb@mail.nih.gov
|
|
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
NCI-09-C-0019
| Principal Investigator: | Referral Contact: | | Elise C. Kohn | Laura D. Otten | | 301-402-2726 | 301-451-1228 1-866-611-6310 (Toll Free) | | ottenl@mail.nih.gov
|
|
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction
NCI-09-C-0003
| Principal Investigator: | Referral Contact: | | Shivaani Kummar | Laura D. Otten | | 301-435-5402 | 301-451-1228 1-866-611-6310 (Toll Free) | | ottenl@mail.nih.gov
|
|
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714)
NCI-08-C-0179
| Principal Investigator: | Referral Contact: | | Elizabeth Fox | Pediatric Oncology | | 301-402-6641 | 1-877-624-4878 (Toll free) | |
|
|
A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors
NCI-08-C-0128
| Principal Investigator: | Referral Contact: | | Giuseppe Giaccone | Janelle Bingham | | 301-496-4916 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas
NCI-08-C-0091
| Principal Investigator: | Referral Contact: | | Giuseppe Giaccone | Janelle Bingham | | 301-496-4916 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas
NCI-08-C-0030
| Principal Investigator: | Referral Contact: | | Shivaani Kummar | Janelle Bingham | | 301-435-5402 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer
NCI-08-C-0007
| Principal Investigator: | Referral Contact: | | Crystal Mackall | Pediatric Oncology | | 301-402-5940 | 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors
NCI-07-C-0220 (A Cooperative Group Study: ADVL0612)
| Principal Investigator: | Referral Contact: | | Elizabeth Fox | Pediatric Oncology | | 301-402-6641 | 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study)
NCI-07-C-0166
| Principal Investigator: | Referral Contact: | | Elizabeth Fox | Pediatric Oncology | | 301-402-6641 | 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas
NCI-07-C-0097
| Principal Investigator: | Referral Contact: | | Shivaani Kummar | Janelle Bingham | | 301-435-5402 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCI-07-C-0054
| Principal Investigator: | Referral Contact: | | Elizabeth Fox | Pediatric Oncology | | 301-402-6641 | 1-877-624-4878 (Toll free) | |
|
|
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
NCI-07-C-0047
| Principal Investigator: | Referral Contact: | | Phillip A. Dennis | Hyejeong Root | | 301-496-0929 | 301-402-0998 | | roothy@mail.nih.gov
|
|
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors
NCI-07-C-0040
| Principal Investigator: | Referral Contact: | | Crystal Mackall | Pediatric Oncology | | 301-402-5940 | 1-877-624-4878 (Toll free) | |
|
|
A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
NCI-06-C-0221
| Principal Investigator: | Referral Contact: | | James Doroshow | Janelle Bingham | | 301-496-4291 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha
NCI-05-C-0186
| Principal Investigator: | Referral Contact: | | Shivaani Kummar | Janelle Bingham | | 301-435-5402 | 301-435-2715 | | jbingham@mail.nih.gov
|
|
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors
NCI-00-C-0121
| Principal Investigator: | Referral Contact: | | John E. Janik | Debbie Draper | | 301-402-2913 | 301-435-8525 | | draperde@mail.nih.gov
|
|
| Phase 0 |
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer
NCI-07-C-0101
| Principal Investigator: | Referral Contact: | | Peter Choyke | Yolanda McKinney | | 301-451-4220 | 301-443-6913 | | ymckinney@mail.nih.gov
|
|
| No Phase |
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy
NCI-09-C-0100
| Principal Investigator: | Referral Contact: | | Aradhana Kaushal | Sharon L. Smith | | 301-496-5457 | 301-496-5457 | | smiths@mail.nih.gov
|
|
The Natural History of Solid Organ Cancer Stem Cells
NCI-09-C-0079
| Principal Investigator: | Referral Contact: | | Itzhak Avital | Melissa Walker | | 301-402-0083 | 301-402-9537 | | walkerme@mail.nih.gov
|
|
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
NCI-07-C-0111
| Principal Investigator: | Referral Contact: | | Deborah Citrin | Sharon L. Smith | | 301-496-5457 | 301-496-5457 | | smiths@mail.nih.gov
|
|
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCI-97-C-0147
| Principal Investigator: | Referral Contact: | | W. Marston Linehan | | | 301-496-6353 | | |
|
|